Pathogenicity of IgG-Fc desialylation and its association with Th17 cells in an animal model of systemic lupus erythematosus.

IL-17 secreting helper T cells Immunoglobulin Fc sialylation Systemic lupus erythematosus animal model nephritis

Journal

Modern rheumatology
ISSN: 1439-7609
Titre abrégé: Mod Rheumatol
Pays: England
ID NLM: 100959226

Informations de publication

Date de publication:
10 Jun 2023
Historique:
received: 19 01 2023
medline: 10 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: aheadofprint

Résumé

Decreased sialylation of IgG Fc glycans has been reported in autoimmune diseases, but its role in systemic lupus erythematosus (SLE) is not fully understood. In this study, we examined the pathogenicity of IgG desialylation and its association with Th17 in SLE using an animal model. B6SKG mice, which develop lupus-like systemic autoimmunity due to the ZAP70 mutation, were used to investigate the pathogenicity of IgG desialylation. The proportion of sialylated IgG was compared between B6SKG and wild-type mice with or without β-glucan treatment-induced Th17 expansion. Anti-IL-23 and anti-IL-17 antibodies were used to examine the role of Th17 cells in IgG glycosylation. Activation-induced cytidine deaminase specific St6gal1 conditional KO (cKO) mice were generated to examine the direct effect of IgG desialylation. The proportions of sialylated IgG were similar between B6SKG and wild-type mice at steady state. However, IgG desialylation was observed after β-glucan-induced Th17 expansion, and nephropathy also worsened in B6SKG mice. Anti-IL-23/17 treatment suppressed IgG desialylation and nephropathy. Glomerular atrophy was observed in the cKO mice, suggesting IgG desialylation is directly involved in disease exacerbation. IgG desialylation contributes to the progression of nephropathy, which is ameliorated by blocking IL-17A or IL-23 in an SLE mouse model.

Identifiants

pubmed: 37300805
pii: 7193780
doi: 10.1093/mr/road054
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Japan College of Rheumatology 2023. Published by Oxford University Press.

Auteurs

Yuri Nishida (Y)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Mirei Shirakashi (M)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Noritaka Hashii (N)

Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.

Ran Nakashima (R)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Yoichi Nakayama (Y)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Masao Katsushima (M)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Ryu Watanabe (R)

Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Hideo Onizawa (H)

Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Ryosuke Hiwa (R)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Hideaki Tsuji (H)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Koji Kitagori (K)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Shuji Akizuki (S)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Akira Onishi (A)

Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Kosaku Murakami (K)

Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Hajime Yoshifuji (H)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Masao Tanaka (M)

Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Tatsuaki Tsuruyama (T)

Department of Drug Discovery Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Akio Morinobu (A)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Motomu Hashimoto (M)

Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Classifications MeSH